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Abstract
Background: Apical Membrane Antigen-1 (AMA1) is one of the leading blood stage malaria vaccine candidates. AMA1-C1/
AlhydrogelH consists of an equal mixture of recombinant AMA1 from FVO and 3D7 clones of P. falciparum, adsorbed onto
AlhydrogelH. A Phase 1 study in semi-immune adults in Mali showed that the vaccine was safe and immunogenic, with
higher antibody responses in those who received the 80 mg dose. The aim of this study was to assess the safety and
immunogenicity of this vaccine in young children in a malaria endemic area.
Design: This was a Phase 1 dose escalating study in 36 healthy children aged 2–3 years started in March 2006 in
Done ´gue ´bougou, Mali. Eighteen children in the first cohort were randomized 2:1 to receive either 20 mg AMA1-C1/
AlhydrogelH or Haemophilus influenzae type b HiberixH vaccine. Two weeks later 18 children in the second cohort were
randomized 2:1 to receive either 80 mg AMA1-C1/AlhydrogelH or Haemophilus influenzae type b HiberixH vaccine.
Vaccinations were administered on Days 0 and 28 and participants were examined on Days 1, 2, 3, 7, and 14 after
vaccination and then about every two months. Results to Day 154 are reported in this manuscript.
Results: Of 36 volunteers enrolled, 33 received both vaccinations. There were 9 adverse events related to the vaccination
in subjects who received AMA1-C1 vaccine and 7 in those who received HiberixH. All were mild to moderate. No
vaccine-related serious or grade 3 adverse events were observed. There was no increase in adverse events with
increasing dose of vaccine or number of immunizations. In subjects who received the test vaccine, antibodies to AMA1
increased on Day 14 and peaked at Day 42, with changes from baseline significantly different from subjects who
received control vaccine.
Conclusion: AMA-C1 vaccine is well tolerated and immunogenic in children in this endemic area although the antibody
response was short lived.
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Introduction
Malaria remains the primary cause of death in children in sub-
Saharan Africa despite the existence of tools such as antimalarial
drugs, insecticide treated bet nets, and indoor residual spraying. It
is estimated that malaria causes between 300 and 500 million
clinical cases and 700,000 to 1.6 million deaths each year [1]. An
effective malaria vaccine is a much needed tool to combat this
disease. With the international effort to develop a malaria vaccine,
several malaria vaccine candidates have reached the stage of
clinical testing in malaria exposed populations. Apical membrane
antigen-1 (AMA1) is a surface protein expressed during the asexual
blood stage of P. falciparum, and is a leading vaccine candidate,
with several formulations being tested in malaria endemic areas in
Africa [2,3]. Preclinical studies have shown that vaccination with
AMA1 induces antibodies and protection against homologous
parasite challenge in both rodent and monkey models of malaria
infection [4,5,6,7,8].
The AMA1-Combination 1 (C1) vaccine used in this study
containsanequalmixtureofthecorrectlyfoldedectodomainportion
of recombinant AMA1 from two different clones of P. falciparum,
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sequence polymorphism of the AMA1 gene and the strain specific
antibody response to recombinant AMA1 [9,10]. It is hoped that the
inclusion of more than one polymorphic protein will induce broader
protection against infection with diverse strains of parasites. Phase 1
studies in malaria naı ¨ve adults in the US and in semi-immune adults
in Mali have shown that the vaccine is safe and immunogenic at a
dose of 80 mg [11,12]. Based on these results, a Phase 1 clinical trial
of this vaccine in children was initiated in a malaria-endemic setting
in Done ´gue ´bougou in Mali, West Africa.
Methods
This was a dose-escalating randomized double blind clinical
trial designed to assess the safety and immunogenicity of the blood
stage malaria vaccine candidate AMA1-C1, adjuvanted with
AlhydrogelH. The protocol for this trial and supporting CON-
SORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Participants
Participants were healthy children available for the duration of
the trial (52 weeks) aged 2 to 3 years old living in the village of
Done ´gue ´bougou, a village with high seasonal malaria transmission
occurring from July to November [13]. Exclusion criteria included
recent or current participation in another investigational vaccine
or drug trial, history of severe allergic reaction or asthma, known
immunodeficiency, recent use of systemic corticosteroids or
immunosuppressive drugs, recent receipt of a licensed vaccine or
blood transfusion, history of splenectomy, previous receipt of an
investigational malaria vaccine or Hemophilus influenza B vaccine,
known thrombocytopenia or bleeding disorder, abnormal screen-
ing laboratories (alanine aminotransferase (ALT) .62 U/L, serum





3, or platelet count ,120,000/mm
3), and
any other clinically significant disease or condition which might
confound the interpretation of study results.
Ethics
Community consent was obtained at a meeting with village
leaders, heads of families, and other community members prior to
the start of the study. Individual informed consent was then obtained
after oral translation of the consent form into the local language.
Understanding of the contents of the consent was confirmed by
means of a multiple choice questionnaire. Parents or guardians
unable to read placed an imprint of his/her finger in place of a
signature; an independent witness also signed all consent forms. The
studywasconductedunder a protocol reviewed and approved by the
Institutional Review Board of the National Institute of Allergy and
Infectious Disease (NIAID), and by the Ethics Committee of the
Faculty of Medicine, Pharmacy and Dentistry, University of
Bamako. The study was submitted to the U.S. Food and Drug
Administration for review as part of Investigational New Drug
application BB-IND#10944. The study was monitored for
regulatory compliance and data quality by the Regulatory
Compliance and Human Subjects Protection Branch of NIAID
and the Initiative for Vaccine Research of WHO. The NIAID Data
Safety Monitoring Board (DSMB) and /or local medical monitor
reviewed safety data prior to next vaccination and dose escalation.
Interventions
Both recombinant cGMP AMA1-FVO and AMA1-3D7 are
62 kDa proteins consisting of amino acids 25 through 545 of the
published sequences of each line’s AMA1 gene (GenBank
accession number AJ277646 for FVO and accession number
U65407 for 3D7). Protein production and vaccine formulation are
described in detail elsewhere [7]. AMA1-C1/AlhydrogelH malaria
vaccine was supplied as a slightly turbid suspension in single-dose
vials. Each 2.0 mL vial contains a single dose, of which 0.5 mL is
the intended volume to be injected. Half mL of vaccine contains
about 424 mg of aluminum (AlhydrogelH, HCI Biosector, Den-
mark) per dose onto which either 20 mgo r8 0mg of recombinant
AMA1-C1 has been bound. The product conforms to established
requirements for endotoxin, sterility, and general safety. The
AMA1-C1/AlhydrogelH research products for this protocol were
supplied by the Pharmaceutical Development Section, Pharmacy
Department, Clinical Center of National Institutes of Health,
where the AMA1-C1/AlhydrogelH vaccine was formulated and
vialed. Both the AMA1-C1/AlhydrogelH and HiberixH (Glax-
oSmithKline, Uxbridge, UK) vaccines were transported and
stored at 0.5uCt o9 uC; temperature recording devices accompa-
nied the vaccines at all times to ensure storage temperature limits
were not violated.
HiberixH is a noninfectious vaccine containing purified capsular
polysaccharide of Haemophilus influenzae type b (Hib) covalently
bound to tetanus toxoid. HiberixH is supplied as a white
lyophilized pellet for reconstitution with sterile saline solution
0.9%. Each 0.5 mL dose contains 10 mg of purified polysaccharide
covalently bound to approximately 30 mg of tetanus toxoid.
HiberixH meets the World Health Organization requirements for
the manufacture of biological substances and Hib conjugate
vaccines. Both vaccines were administered IM in the thigh muscles
on Days 0 and 28, in alternating legs.
Outcomes: Safety and Tolerability
Local and systemic adverse events were recorded and graded
by severity and relationship to vaccine. Volunteers remained in
the study clinic for at least 30 minutes after each immunization
to evaluate for immediate adverse reactions. Follow up visits
were scheduled for Days 1, 2, 3, 7, and 14 after each vaccination,
and at study weeks 12, 22, 30, 42, and 52. Solicited injection site
reactions were pain, erythema, and swelling; solicited general
adverse events were fever, headache, nausea, malaise, myalgia,
arthralgia, urticaria, drowsiness, irritability, and loss of appetite.
Investigators also recorded any other adverse events which
occurred during the follow up period. Injection site erythema,
swelling, and induration were graded as follows: 0=absent,
1=0–20 mm, 2=.20–50 mm, 3=.50 mm. Fever (axillary)
w a sg r a d e da s0=,37.5uC, 1=37.6–38uC, 2=.38–39uC, and
3=.39uC. Pain and solicited adverse events other than fever
and urticaria were graded as follows: 0=absent/none, 1=easily
tolerated, 2=interferes with daily activity, 3=prevents daily
activity. Non-solicited adverse events were graded as 0=none,
1=no effect on activities of daily living, 2=partial limitation in
activities of daily living, or minimal intervention required,
3=activities of daily living limited to ,50% of baseline, or
medical evaluation with intervention required. Hematological
(Hb, WBC, and platelets) and biochemical (ALT, and creati-
nine), laboratory parameters were measured at screening, on
days of immunization, and on Days 3 and 14 after each
vaccination. Hematology was also performed on Day 7 after
each vaccination and at weeks 12, 22, 30, 42, and 52. Serious
adverse events (SAEs) were defined as any adverse event
resulting in death, life threatening, requiring hospitalization,
resulting in disability or incapacity, or any other event which
required intervention to prevent such outcomes.
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Antibody responses to the AMA1 antigens were measured in
plasma by enzyme linked immunosorbent assay (ELISA) at Days
0, 14, 42, 98 and 154. The ELISA technique used was described
previously [11]. A human anti-AMA1 standard plasma was made
using a pool of plasma from 3 individuals receiving AMA1-C1
immunization in a US vaccine trial (manuscript in preparation).
The standard pool was assigned 460.9 ELISA units on AMA1-
FVO and 578.0 units on AMA1-3D7.The minimal detection level
of this assay was 28 ELISA units and all data less than 28 ELISA
units were assigned a value of 14 units for statistical analysis.
Sample size
Sample size for the Phase 1 part of the study was based on safety
outcomes. Group sizes of 10 provide an 80% likelihood of detecting
adverse events that occur with a frequency of 15%. An extra two
subjects per group were included in case of loss to follow up.
Randomization
Participants in the two treatment cohorts (20 mg AMA1-C1/
Alhydrogel and 80 mg AMA1-C1/Alhydrogel) were randomized
in a 2:1 ratio to receive either the study vaccine or the control
(HiberixH). Randomization codes were created by the study
statistician, and randomization occurred at the time of first
vaccination. A copy of the randomization code was provided to
the pharmacist who used coded labels for the vaccines, and to the
medical monitor and DSMB.
Blinding
The study was double blinded, with both participants and
investigators unaware of treatment assignment until completion of
the study. Since the appearance of the vaccines was slightly
different, opaque tape was placed over the syringe so that
investigators were unable to see the contents. Unblinding of the
investigators occurred after adverse event and immunologic
databases to Day 154 were cleaned and finalized.
Statistical methods
Exact Jonckheere–Terpstra (J-T) tests were performed to
examine dose-response relationships for adverse events, according
to dose of AMA1-C1 vaccine (control, low dose, and high dose) for
eachcategoryofAEand totalnumberofAEs.Foreach AEcategory
tested, each subject was defined as having a response of no AE,
grade 1 AE, grade 2 AE, grade 3 AE or SAE based on the subjects
highest grade of AE in that category. In order to maintain a low
threshold for detecting safety concerns no correction was made for
multiple comparisons. For each subject, the arithmetic average of
the FVO and 3D7 ELISA responses at each day was used as that
subject’s AMA1-C1 antibody response for that day. The primary
immunological outcome in this trialwasthe differencein AMA1-C1
antibody response between Day 42 and Day 0. Dose response was
tested by exact J-T test. Similar J-T tests were performed for other
vaccine days using the differences in antibody response between
other time points (Days 14, 98 and 154) and Day 0. All ELISA data
for two subjects were excluded from the antibody response analyses,
because there appeared to be specimen mishandling in those two
cases. The decision to exclude these subjects was made before
unblinding. No other subjects were excluded from the immunoge-
nicity analysis, and those two subjects were included in all safety
analyses. The concordance between log transformed antibody levels
against AMA1-FVO and AMA1-3D7 was measured with random
marginal agreement coefficients with squared difference as
suggested in Fay (2005) [14].
Results
Participant Flow and Baseline Data
Seventy seven children were screened for inclusion in the study,
of whom 36 (19 males and 17 females) were enrolled (Figure 1).
Figure 1. CONSORT Flow Chart.
doi:10.1371/journal.pone.0001563.g001
Phase 1 of AMA1-C1 in Children
PLoS ONE | www.plosone.org 3 February 2008 | Volume 3 | Issue 2 | e1563Reasons for exclusion were concurrent illness (n=13), positive
serology for chronic hepatitis B or C (n=8), hemoglobin ,8.5 g/
dL and/or malnutrition (n=6), other abnormal screening
laboratory tests (n=7), age outside the specified range (n=6),
and one subject was eligible but not enrolled as enrollment was
complete. The first cohort (12 subjects receiving 20 mg AMA1-
C1/Alhydrogel and 6 subjects receiving HiberixH) was vaccinated
on March 16, 2006 and the second cohort (12 subjects receiving
80 mg AMA1-C1/Alhydrogel and 6 receiving HiberixH) was
vaccinated about 2 weeks later. The second vaccination of the
2
nd cohort was completed about 2 months prior to the start of
malaria transmission season. Three subjects (1 in HiberixH group
and 2 in the 80 mg dose group) did not receive the second
vaccination due to acute Hepatitis A infection. All the participants
completed followed up to Day 154.
Safety
Both doses oftheAMA1-C1vaccine werewell tolerated(Table 1).
A total of 9 adverse events that were considered definitely, probably
or possibly related to the vaccination occurred in 7 subjects who
received the AMA1-C1 vaccine. Most (5/9) were local injection site
reactions.Allweremildtomoderateinseverityandresolvedwithin4
days except one case of elevated ALT that persisted through the end
of the follow up period. This subject was enrolled with ALT of
47.3 U/L (near the upper limit of normal range 49.6 U/L). His
ALT increased to 72.8 U/L at Day 3, decreased to 59.4 U/L on
Day 14 but remained slightly above the normal range throughout
the follow up period. Tests for hepatitis A, B and C in this individual
were repeatedly negative. As no apparent etiology was found it was
classified as possibly related to the vaccination. There was no
significant relationship between AMA1-C1 dose and either severity
of AE overall or in any specific category of AEs. There were no
severe or serious adverse event deemed related to the vaccination in
any group. Three serious adverse events (one in each group) were
reported. All were related to acute viral Hepatitis A (two
hospitalizations and one Grade 4 elevation of ALT protocol defined
as an SAE) and were considered unrelated to the vaccination.
IgG responses to AMA1-3D7 and AMA1-FVO
Antibody levels against AMA1-3D7 and AMA1-FVO were
measured by ELISA at Day 0 prior to vaccination, Days 14, 42, 98
and 154. Data for two subjects (one in the HiberixH group and
another in the 80 mg AMA1-C1 dose group) were excluded
because of a labeling error on study Day 42. Of the 34 subjects
considered for the immunology analysis, pre-existing antibodies to
AMA1-FVO and AMA1-3D7 were detectable in 14 (5 in the
HiberixH group, 4 in the 20 mg dose group and 5 in the 80 mg dose
group) and 17 (7 in the HiberixH group, 4 in the 20 mg dose group
and 6 in the 80 mg dose group) respectively. Three subjects (two in
the HiberixH group and one in the 20 mg dose group) had high
antibody levels (greater than 1000 units) prior to vaccination.
Individual antibody values for the FVO and 3D7 antigens are
shown in Table 2. Using all 34 subjects, there was high
concordance between the log transformed antibody response to
AMA1 FVO and AMA1 3D7 both before [0.92 with 95% C.I.
(0.85, 0.96) at Day 0] and after vaccinations [0.96 with 95% C.I.
(0.93, 0.98) at Day 42].
For the test vaccine, an increase in the average of FVO and 3D7
responses was seen at Day 14 and continued to increase after the
second vaccination (Day 42), but decreased by Days 98 and 154
(Figure 2). In the 20 mg group, the geometric mean antibody
response (average FVO and 3D7) increased from 29.0 antibody
units (95% CI 12–68.3) on Day 0 to 171.0 units (95% CI 76.6–
372.3) on Day 14 and to 483 units (95% CI 319.7–729.7) on Day
42. Similarly, in the 80 mg dose group the mean antibody response
increased from 27.5 units (95% CI 17.5–42.0) to 151.7 units (95%
CI 62.7–367.4) and to 317.9 units (95% CI 113.1–893.9) on Day
42 while the corresponding mean antibody levels in the HiberixH
group were 73.1 units (95% CI 19.0–281.4), 63.8 units (95% CI
17.0–238.8) and 49.8 units (95% CI 15.8–157.3). The dose
responses were significant at Days 14 and 42 (p values 0.0003,
0.0008, respectively).
Although there were still statistically significant dose responses
at Days 98 (p=0.0026) and 154 (p=0.0170), by Day 98 the
antibody responses in the 20 mg and 80 mg dose groups decreased
Table 1. Local injection site, systemic and laboratory adverse events judged definitely, probably, or possibly related to vaccine
after vaccination with the AMA1-C1/AlhydrogelH or HiberixH vaccines.














(n=10) 20 mg8 0 mg
Local
Pain 1 1 1 0 1 0 1 2 1
Swelling 1 0 0 1 0 0 2 0 0
Erythema 1 0 1 0 0 0 1 0 1
Systemic
Fever 0 0 1 1 0 0 1 0 1
Vomiting 0 0 1 0 0 0 0 0 1
Anorexia 0 0 1 0 0 0 0 0 1
Drowsiness 0 0 1 0 0 0 0 0 1
Laboratory
Elevated WBC 1 0 0 0 0 1 1 0 1
Elevated ALT 1 0 0 0 0 0 1 0 0
doi:10.1371/journal.pone.0001563.t001
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subjects who received HiberixH, with geometric means of 127.3
(95% CI 73.2–221.2) in the 20 mg dose group, 94.0 (95% CI 43.2–
205.0) in the 80 mg dose and 35.2 (95% CI 12.2–102.0) in the
HiberixH group. These levels decreased further by Day 154.
Discussion
Interpretation
This Phase 1 study of AMA1-C1 adjuvanted with Alhydrogel at
the dose of 20 and 80 mg in malaria exposed children in Mali
showed that the vaccine was well tolerated, with no vaccine related
severe or serious adverse event. This is consistent with the findings
in two previous Phase 1 trials in malaria naı ¨ve and semi-immune
adults [11,12].
The vaccine induced antibodies to both constituent alleles, with
responses to AMA1-FVO and AMA1-3D7 that were highly
correlated, as seen in previous studies [11,12]. Responses were
seen 2 weeks after the first vaccination and further increased after
the second vaccination. This is different from the study in malaria-
naı ¨ve US adults [11], where no responses were seen after the first
vaccination. This is likely due to prior malaria exposure, as shown
by pre-existing antibody in 59% of subjects overall at baseline.
Antibody responses after only one dose were also seen in semi-
immune Malian adults [12]. However, compared to Malian
adults, antibody levels were much lower overall both at baseline
and after immunizations (geometric means of 1081.5 and 2634.9
units respectively at baseline and Day 42 in the 80 mg dose adult
group) likely due to less prior exposure to malaria in children
Table 2. ELISA antibody values in plasma from volunteers on selected time points.
AMA1-FVO AMA1-3D7
Subject no Vaccine Day 0 Day 14 Day 42 Day 98 Day 154 Day 0 Day 14 Day 42 Day 98 Day 154
1* Hiberix 14 14 63 14 35 32 14 40 14 73
6 1 4 1 41 4 1 4 1 41 41 41 41 41 4
8 1 4 1 41 4 1 4 1 41 41 41 41 41 4
10 14 14 14 14 14 14 14 14 14 14
13 14 14 14 14 70 14 14 14 14 157
14 33 33 14 14 14 58 47 14 14 14
25 365 263 84 14 14 305 215 78 14 14
28 14 14 14 14 85 36 29 14 14 80
30 257 249 199 450 167 123 115 88 175 74
32 1573 1175 663 362 419 2386 2340 1110 605 613
33 2416 1928 1175 471 451 2608 2084 1175 453 642
22 0 mg 14 82 273 48 46 14 127 239 65 52
3 14 53 144 14 113 14 77 187 30 91
4 14 565 927 187 127 14 824 997 193 139
5 28 140 251 81 40 14 131 193 54 14
7 14 127 384 70 35 14 112 413 102 14
9 14 64 397 155 82 14 279 1188 492 252
11 2043 1480 1051 408 274 462 530 687 264 176
12 14 81 627 302 218 28 119 724 249 154
15 14 70 300 219 230 14 121 561 244 200
16 120 681 1427 325 174 52 425 1134 258 148
17 14 14 356 98 32 14 14 225 67 14
18 62 545 471 54 14 77 742 730 104 14
19 80 mg 29 47 114 32 14 73 110 192 56 30
20 14 58 157 37 14 14 67 201 39 14
22* 68 177 144 40 125 50 199 292 91 111
23 31 46 156 79 397 14 34 167 117 1009
24* 14 34 14 14 14 14 14 14 14 14
26 14 245 530 167 93 68 958 1520 453 214
27 14 37 113 14 14 14 143 275 84 32
29 30 85 181 36 78 31 82 224 64 79
31 115 597 2640 454 146 49 268 1258 227 78
34 14 288 746 157 168 14 248 780 228 156
35 14 1983 3944 679 1200 29 2243 4348 674 1053
*did not received the second vaccination due Hepatitis A.
doi:10.1371/journal.pone.0001563.t002
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at all time points tested, mean antibody levels for the 20 mg and
80 mg dose groups at Days 14 and 42 were similar, as shown by
substantially overlapping confidence intervals.
In the US adult study with the same vaccine, as in other malaria
vaccine studies in children [15,16,17], highest antibody responses
wereseenafter thethirddose of vaccine, anditispossiblethata third
dose is also needed in children in this endemic area, although in the
Malian adult study with the same vaccine limited boosting was seen
afterthethirddose[12].ShorthalflivesofIgG1andIgG3antibodies
to merozoite antigens in children living in endemic areas have been
reported in epidemiological studies in Mali [18] and in Kenya [19].
In the Kenya study the mean half lives of IgG1 and IgG3 in children
after severe malaria attack were 9.1 days (95% CI 7.6 and 12.0) and
6.1 days (95% CI 3.7–8.4 days) with little or no boosting after re-
infection. Further studies are needed on the mechanisms of the
immune response to merozoite antigens as well as the dynamics of
these responses and their relationship to malaria infection and
disease. Additionally, the ability of vaccination to induce a long term
memory response should be further investigated.
Generalizability
This is the first Phase 1 study of an AMA 1 vaccine in children.
It aimed to provide information on the safety and immunogenicity
Figure 2. Average of FVO and 3D7 ELISA responses by Vaccine Day. Gray lines are individual subjects, black lines are geometric means
within each randomization group.
doi:10.1371/journal.pone.0001563.g002
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to a larger Phase 2b study. The study population was chosen to
represent young children living in an area with seasonal intense
malaria transmission and the results should be broadly general-
izable to such populations. Like any Phase 1 study, it is powered to
detect only frequent events or large differences. After reviewing the
safety data in this study, a Phase 2 study was initiated. The Phase 2
study will provide further information on the safety and the
immunogenicity of the AMA1-C1/Alhydrogel vaccine, as well as
the biologic impact on parasitemia during the malaria transmis-
sion season. Although there is an increase in antibody in subjects
who received the AMA1-C1 vaccine, the level of antibody that
would lead to protection is unknown.
Overall evidence
This trial provided the first data on the safety and immunoge-
nicity of AMA1–C1 vaccine in malaria exposed children. It shows
that the vaccine is well tolerated and immunogenic although the
duration of the induced antibody is short. The absence of safety
concerns has justified a Phase 2b study. In addition to assessing
biologic impact, the Phase 2b study will provide more information
on both safety and immunogenicity as well as whether or not
immunization during the transmission season leads to higher
antibody responses to AMA1.
Supporting Information
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0001563.s001 (0.19 MB
PDF)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0001563.s002 (0.45 MB
PDF)
Acknowledgments
We are very grateful to the children who participated in the study their
parents and the population of the village of Done ´gue ´bougou as well as all of
the MRTC staff and the district health officer of Kati. Special thanks to
Gary Mays, Dick Sakai, Ydrissa Sow, Souleymane Karembe and Etsegenet
Meshesha for their logistical and managerial support.
We are also very thankful to Dr. Marie Paul Kieny and Dr. Zarifah
Reed at Initiative for Vaccine Research/WHO for providing the control
vaccine through GSK as well as additional independent monitoring of this
study. Our gratitude goes to the local Medical Monitor Dr. Tatiana Keita,
the WHO monitor Dr. Laurence Yamuah, the NIAID/NIH DSMB
members (chaired by Dr Bill Blackwelder) and Dr. Christopher V Plowe
for their wise technical advice.
Results were presented in part at the American Society of Tropical
Medicine and Hygiene 54
th Annual Meeting, December, 2006.
Author Contributions
Conceived and designed the experiments: LM AS OD DD IS ADicko MF
MB ADolo RE KM GM. Performed the experiments: OD DD IS ADicko
MSogoba MN OG MB MSissoko ADolo RE BK GM MP. Analyzed the
data: LM AS OD IS ADicko MF RE KM MP. Contributed reagents/
materials/analysis tools: LM AS DD MSogoba MN OG MB MSissoko
ADolo KM BK GM. Wrote the paper: LM AS OD DD IS ADicko MF
MSogoba MN OG MB MSissoko ADolo RE KM BK GM MP.
References
1. World Health Organization. Annex Table 3: Burden of disease in DALYs by
cause sex and mortality stratum in the WHO regions, estimates for 2001. World
Health Report 2002: Reducing risks, Promoting Healthy life. Geneva: World
Health Organization, 192–197.
2. Girard MP, Reed ZH, Friede M, Kieny MP (2007 Feb 19) A review of human
vaccine research and development: malaria. Vaccine 25(9): 1567–80. Epub 2006
Oct 5.
3. Epstein JE, Giersing B, Mullen G, Moorthy V, Richie TL (2007 Feb) Malaria
vaccines: are we getting closer? Curr Opin Mol Ther 9(1): 12–24.
4. Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, et al. (1994)
Protective immunity induced in squirrel monkeys with recombinant apical
membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 51: 711–9.
5. Crewther PE, Matthew ML, Flegg RH, Anders RF (1996) Protective immune
responses to apical membrane antigen 1 of Plasmodium chabaudi involve
recognition of strain-specific epitopes. Infect Immun 64: 3310–7.
6. Narum DL, Ogun SA, Thomas AW, Holder AA (2000) Immunization with
parasite-derived apical membrane antigen 1 or passive immunization with a
specific monoclonal antibody protects BALB/c mice against lethal Plasmodium
yoelii yoelii YM blood-stage infection. Infect Immun 68: 2899–906.
7. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, et al. (2002) In vitro
studies with recombinant Plasmodium falciparum apical membrane antigen 1
(AMA1): production and activity of an AMA1 vaccine and generation of a
multiallelic response. Infect Immun 70: 6948–60.
8. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, et al. (2002)
Vaccination of monkeys with recombinant Plasmodium falciparum apical
membrane antigen 1 confers protection against blood-stage malaria. Infect
Immun 70: 6961–7.
9. Kocken CH, Narum DL, Massougbodji A, Ayivi B, Dubbeld MA, et al. (2000)
Molecular characterisation of Plasmodium reichenowi apical membrane
antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-
mediated inhibition of red cell invasion. Mol Biochem Parasitol 109: 147–56.
10. Cortes A, Mellombo M, Mueller I, Benet A, Reeder JC, et al. (2003)
Geographical structure of diversity and differences between symptomatic and
asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1.
Infect Immun 71: 1416–26.
11. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, et al. (2005)
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage
vaccine for Plasmodium falciparum malaria. Infect Immun 73: 3677–85.
12. Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, et al. (2007 Oct 17)
Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in
Adult Malians. PLoS ONE 2(10): e1045.
13. Dicko A, Sagara I, Diemert D, Sogoba M, Niambele MB, et al. (2007 Dec 1,
Dec) Year-to-year variation in the age-specific incidence of malaria in two
potential vaccine testing sites in Mali with different levels of malaria transmission
intensity. Am J Trop Med Hyg 77(6): 1028–1033.
14. Fay MP (2005) Random marginal agreement coefficients: rethinking the
adjustment for chance when measuring agreement. Biostatistics 6: 171–180.
15. Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, et al. (2005
Jul 14) Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine
in Gambian children. Vaccine 23(32): 4148–57. Epub 2005 Apr 15.
16. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, et al. (2006
Nov 24) Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A
Randomized Phase Ib Dose-Escalation Trial in Kenyan Children. PLoS Clin
Trials 1(7): e32.
17. Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, et al. (2007
Jan) Safety and immunogenicity of the RTS,S/AS02A candidate malaria
vaccine in children aged 1–4 in Mozambique. Trop Med Int Health 12(1):
37–46.
18. Fruh K, Doumbo O, Muller HM, Koita O, McBride J, et al. (1991 Apr) Human
antibody response to the major merozoite surface antigen of Plasmodium
falciparum is strain specific and short-lived. Infect Immun 59(4): 1319–24.
19. Kinyanjui SM, Conway DJ, Lanar DE, Marsh K (2007 Jun 28) IgG antibody
responses to Plasmodium falciparum merozoite antigens in Kenyan children
have a short half-life. Malar J 6: 82.
Phase 1 of AMA1-C1 in Children
PLoS ONE | www.plosone.org 7 February 2008 | Volume 3 | Issue 2 | e1563